Kymriah
Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma
December 7, 2020Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis
Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …
Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma
August 4, 2020Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy
Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …
Top Ten most popular articles on Pharmafile.com this week!
August 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma
Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Novartis’ Kymriah to be covered by Japan’s national insurance system
May 16, 2019Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah
March 12, 2019Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK
Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …
Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma
February 1, 2019Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma
NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …
Canada Health approves Novartis’ CAR-T therapy Kymriah
January 18, 2019Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Top Ten most popular articles on Pharmafile.com this week!
November 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10
The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
Novartis strike $40m deal with Chinese firm Cellular Biomedicine
September 28, 2018Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …
NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
NICE rejects CAR-T therapy Kymriah for DLBCL in adults
September 19, 2018Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …
